Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Growth hormone secretagogues: The clinical future
Autore:
Micic, D; Casabiell, X; Gualillo, O; Pombo, M; Dieguez, C; Casanueva, FF;
Indirizzi:
Univ Santiago Compostela, Sch Med, Dept Med, Endocrine Sect, E-15780 Santiago De Compostela, Spain Univ Santiago Compostela Santiago De Compostela Spain E-15780 ela, Spain Univ Santiago Compostela, Sch Med, Dept Physiol, E-15780 Santiago De Compostela, Spain Univ Santiago Compostela Santiago De Compostela Spain E-15780 ela, Spain Univ Santiago Compostela, Sch Med, Dept Pediat, E-15780 Santiago De Compostela, Spain Univ Santiago Compostela Santiago De Compostela Spain E-15780ela, Spain Univ Santiago, Complejo Hosp, Santiago De Compostela, Spain Univ SantiagoSantiago De Compostela Spain antiago De Compostela, Spain Inst Endocrinol, Belgrade, Yugoslavia Inst Endocrinol Belgrade Yugoslavia st Endocrinol, Belgrade, Yugoslavia
Titolo Testata:
HORMONE RESEARCH
, volume: 51, anno: 1999, supplemento:, 3
pagine: 29 - 33
SICI:
0301-0163(1999)51:<29:GHSTCF>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
GH-RELEASING HORMONE; (GH)-RELEASING PEPTIDE; OBESE SUBJECTS; SECRETION; CHILDREN; HEXARELIN; RESPONSES; GHRP-6; HEXAPEPTIDE; L-692,429;
Keywords:
growth hormone secretagogues; growth hormone releasing peptide-6; growth hormone; therapeutic; diagnostic;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
34
Recensione:
Indirizzi per estratti:
Indirizzo: Micic, D Univ Santiago Compostela, Sch Med, Dept Med, Div Endocrine, E-15780 Santiago De Compostela, Spain Univ Santiago Compostela Santiago De Compostela Spain E-15780 n
Citazione:
D. Micic et al., "Growth hormone secretagogues: The clinical future", HORMONE RES, 51, 1999, pp. 29-33

Abstract

Growth hormone (GH) releasing hexapeptide (GHRP)-6 and other peptidergic and non-peptidergic compounds collectively designated GH secretagogues (GHS)are potent releasers of GH in man. Their clinical future may be envisionedin th ree areas: therapy of GH-deficient (GHD) states, diagnosis of GHD, and non-endocrinological actions, As therapeutic agents and compared with GHitself, GHS have the disadvantage of lower potency but have a more physiological and safer profile of GH secretion. GHS administration could be indicated for states in which medium GH doses have been shown to be effective. As a diagnostic tool, the combined administration of GH releasing hormone plus GHRP-6, both at saturating doses, is currently the most powerful releaser of GH, devoid of side effects and convenient for the patient; it may alsobe an alternative to the insulin tolerance test for the diagnosis of GHD in adult patients. Their potential action at cardiovascular level is highly promising. Although the clinical future of GH releasing substances is appealing, probably the most relevant contribution has yet to be discovered. Once the endogenous ligand of the GHS receptor is identified, we will have an insight into the real hypothalamic control of GH secretion in man. With this knowledge it is likely that some diagnostic and therapeutic actions that are commonly undertaken will significantly change. Copyright (C) 1999 S. Karger AG, Basel.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/07/20 alle ore 14:19:29